Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Source Data
Transparent Process
Open Access

Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice

Yaser Salaymeh, Marganit Farago, Shulamit Sebban, Batel Shalom, Eli Pikarsky, View ORCID ProfileShulamit Katzav  Correspondence email
Yaser Salaymeh
1Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University Hadassah Medical School, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marganit Farago
1Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University Hadassah Medical School, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shulamit Sebban
1Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University Hadassah Medical School, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Batel Shalom
1Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University Hadassah Medical School, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eli Pikarsky
2The Lautenberg Center for Immunology and Cancer Research and Department of Pathology, Institute for Medical Research Israel-Canada, The Hebrew University Hadassah Medical School, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shulamit Katzav
1Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University Hadassah Medical School, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shulamit Katzav
  • For correspondence: shulamitk@ekmd.huji.ac.il
Published 10 April 2020. DOI: 10.26508/lsa.202000661
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Supplementary Materials
  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. Plasmid construction and validation.

    (A) Wild-type Vav1 was subcloned into Teto7minCMV plasmid transgene plasmid fused to GFP (tetO–Vav1). (B) HEK293 cells were transfected with the tetO–Vav1 plasmid and a vector that encodes the reverse tetracycline responsive transactivator (rtTA). After treatment with Dox, the cells were lysed and analyzed by Western blotting for the presence of Vav1 and its phosphotyrosine status. The empty plasmid served as control vector. (C) HEK293 cells were transfected with the tetO–Vav1 plasmid either treated (+) or nontreated (−) with Dox were subjected to immunofluorescence. Green = GFP, which refers to Vav1 expression. Scale bar represents 50 μm.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. Validation of tissue-specific expression of Vav1 transgene in vivo.

    Western blot analysis of liver and spleen tissue from tetO–Vav1 mice crossed with LAP–rtTA mice (tetO–Vav1/LAP–rtTA; positive mice) with anti-Vav1, anti-GFP expression (indicative of the transgene Vav1 expression) and anti-actin Abs.

    Source data are available for this figure.

    Source Data for Figure S2[LSA-2020-00661_SdataFS2_1.pdf][LSA-2020-00661_SdataFS2_2.pdf][LSA-2020-00661_SdataFS2_3.pdf]

  • Fig 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 1. Expression of GFP in the pancreata from different mouse lines.

    Representative paraffin sections of the pancreata of the various mouse lines at different time points after the onset of transgene induction (as indicated) were stained with anti-GFP Abs that identify the Vav1 transgene. Scale bar represents 25 μm. Number of mice stained in this experiment are outlined in Table S1.

  • Figure S3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S3. Expression of endogenous Vav1 in the K-RasG12Dmouse pancreas.

    (A) Paraffin sections of pancreata from a control mouse (at 1-mo post tamoxifen and Dox administration) and from K-RasG12D mice at the indicated time points after transgene induction were stained with anti-Vav1 antibodies and then assessed for endogenous Vav1 expression. A representative of each of those stained sections is depicted. Scale bar represents 50 μm. (B) Endogenous Vav1 expression was quantified by counting Vav1-positive acinar and ductal cells in K-RasG12D mice at different times after transgene induction: at 1 mo (n = 2), 2 mo (n = 4), 3.5 mo (n = 3), 5 mo (n = 3), and 12 mo (n = 3). Five randomly chosen fields were counted in mouse sections (scale bar represents 50 μm). Calculated mean values of Vav1-positive acinar/ductal cells at each time point are represented in the graph. SEM are shown.

  • Fig 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 2. Vav1 and K-RasG12D synergize in the generation of malignant pancreatic lesions.

    Hematoxylin and eosin (H&E)–stained pancreata of control, Vav1, K-RasG12D, and K-RasG12D/Vav1 mice, at 1, 2, 3.5, 5, and 12 mo after the onset of transgene induction were analyzed for the appearance of malignant lesions. (A) Representative pictures of H&E–stained sections taken 3.5 mo after the onset of transgene induction are shown. Scale bar represents 20 μm. (B) The extent of malignant lesions generated in K-RasG12D and K-RasG12D/Vav1 mice at the indicated time points after onset of transgene induction was calculated. The sum of area occupied by ADM, PanINs, and PDAC lesions (APPD) was measured as a fraction of the total area of the pancreas (APPD%). Numbers of K-RasG12D and K-RasG12D/Vav1 mice used, respectively, were n = 4 and n = 8 at 1 mo; n = 6 and n = 8 at 2 mo; n = 13 and n = 17 at 3.5 mo; n = 9 and n = 9 at 5 mo; and n = 7 and n = 5 at 12 mo. Significant differences between the two analyzed groups (P < 0.05; t test) are indicated. N.S. refers to statistical nonsignificant differences. SEM are shown.

  • Figure S4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S4. K-RasG12D/Vav1 mice were either treated with tamoxifen and Dox (+Dox) or treated with tamoxifen only (−Dox).

    5 mo after Vav1 transgene induction, the mice were euthanized and their pancreata was analyzed for the appearance of malignant lesions. (A) A representative picture of hematoxylin and eosin (H&E) sections of pancreas from these mice at two magnifications: upper panel scale bar represents 500 μm and lower panel scale bar represents 200 μm. (B) The extent of malignant lesions generated in K-RasG12D/Vav1 mice either expressing both K-RasG12D and Vav1 (+Dox; n = 9) or expressing K-RasG12D (−Dox; n = 3) only is presented as a histogram. At the time point of 5 mo post-transgene induction. SEM and significance between the two groups analyzed are indicated (t test).

  • Fig 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 3. Vav1 expression enhances pancreatic ductal adenocarcinoma (PDAC) generation in the K-RasG12D/Vav1 mouse pancreas and is critical for pancreatic malignant lesions.

    (A) Representative K-RasG12D (left) and K-RasG12D/Vav1 (right) stained with anti–pan-cytokeratin Abs are shown. The presence of PDAC is shown in a representative pancreatic section from a K-RasG12D/Vav1 mouse 1 mo after transgene induction (square, right panel). Scale bar represents 20 μm. (B) The extent of PDAC present in K-RasG12D and K-RasG12D/Vav1 mice at the different time points after transgene induction was assessed. The histogram summarizes the incidence of PDAC development in K-RasG12D mice and in K-RasG12D/Vav1 mice. Two of 26 K-RasG12D mice (7.7%) and 12 of 39 K-RasG12D/Vav1 mice (30.8%) had developed PDAC lesions. PDAC developed in K-RasG12D/Vav1 ranging from 1 to 12 mo post transgenes induction, whereas PDAC in K-RasG12D developed in mice of 3.5 and 5 mo post transgene induction. Significance of the difference between them (P < 0.05) was calculated using a two-tailed chi-squared test (Fisher’s exact test). (C) In some K-RasG12D/Vav1 mice (see numbers below), before completion of 3.5 mo of transgene induction, their Vav1 expression was discontinued for 20 d by removal of Dox from their drinking water (−Dox). Hematoxylin and eosin (H&E) staining of the pancreata of K-RasG12D and K-RasG12D/Vav1 either treated with Dox and tamoxifen (+Dox) or in which Dox was removed from their drinking water for 20 d before completion of 3.5 mo of transgene induction (−Dox) was performed. All the mice were then analyzed for the appearance of malignant lesions. The number of malignant lesions generated in these mice was calculated as APPD%, both for those treated with Dox (+Dox; n = 13 and n = 17, respectively) and for those in which Dox was omitted for 20 d (−Dox; n = 3 and n = 7, respectively). Significant differences between the two analyzed groups (P < 0.05; t test) are indicated. N.S. refers to statistical nonsignificant differences. SEM are shown. (D) Pancreatic sections from K-RasG12D/Vav1 mice after 3.5 mo post transgene induction either treated with Dox (+Dox) or in which Dox treatment was discontinued for 20 d (−Dox) were either stained by H&E (upper panel) or anti-GFP Abs (lower panel). Representative pictures are shown. Scale bar represents 200 μm.

  • Fig 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 4. Proliferation of pancreatic cells from control, Vav1, K-RasG12D, and K-RasG12D/Vav1 mice.

    Proliferation of acinar and ductal pancreatic cells obtained, at different times after initiation of transgene induction, from control, Vav1, K-RasG12D, and K-RasG12D/Vav1 mice was assessed by anti-Ki-67 staining. (A) Representative pictures of Ki-67–stained pancreatic sections taken from mice 5 mo after the start of transgene induction. Scale bar represents 50 μm. (B) Proliferation was quantified by counting 10 fields from each pancreatic section and calculating the mean value. The numbers of mice used for Ki-67 staining calculations are recorded in Table S1. To obtain the Ki-67 staining ratio in each case, the result at each time point was divided by the result obtained for the control at the same time point. Significant differences between the two analyzed groups (P < 0.05; t test) are indicated. N.S. refers to statistical nonsignificant differences. SEM are shown.

  • Fig 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 5. Staining of phospho-EGFR and phospho-Erk in malignant pancreatic lesions from K-RasG12D/Vav1 mice.

    (A) Pancreatic sections from 4 K-RasG12D and 8 K-RasG12D/Vav1 mice treated with tamoxifen and Dox for 5 mo were stained for pEGFR (upper panel) and total EGFR (lower panel). Representative pictures at two magnifications are shown. The scale bars represent either 50 μm (left pictures in each group) or 20 μm (right pictures in each group) as indicated. (B) Pancreatic sections from K-RasG12D and K-RasG12D/Vav1 mice treated with tamoxifen and Dox for 5 mo were stained for pERK. Representative pictures are shown. Scale bar represents 20 μm. (C) Lysates from pancreatic tissues of 5-mo post-transgene induction from 3 control, 2 Vav1, 3 K-RasG12D, and 2 K-RasG12D/Vav1 mice were Western blotted using anti–phospho-Erk and anti-Erk (left panel). A representative blot from four independent experiments is shown. Relative Erk phosphorylation in the pancreata of control, Vav1, K-RasG12D, and K-RasG12D/Vav1 mice at 1, 2, 3.5, and 5 mo after the onset of transgene induction was calculated by quantifying their Western blots using ImageJ 1.49V software (right panel). Number of mice in these experiments are outlined in Table S1. SEM are shown.

  • Fig 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 6. Activation of Rac–GTP in malignant pancreatic lesions from K-RasG12/Vav1 mice.

    Rac1–GTP activation in the pancreata of control, Vav1, K-RasG12D, and K-RasG12D/Vav1 mice was analyzed. (A) Western blotting using anti–Rac1–GTP Abs, anti-Rac1, and anti-actin were used to evaluate Rac1–GTP levels in protein lysates from pancreatic tissues of control, Vav1, K-RasG12D, and K-RasG12D/Vav1 mice (two mice in each group) at 5 mo after transgene induction. The vertical black lines delineate sliced images that juxtapose lanes that were nonadjacent in the gel. (B) The levels of Rac1–GTP versus total Rac1 at the pancreata of control, Vav1, K-RasG12D, and K-RasG12D/Vav1 mice at 1, 2, 3.5, and 5 mo after initiation of transgene induction were calculated. Each Rac1–GTP/Rac1 was then divided by the control ratio. Band intensity of the Western blots was quantified using ImageJ 1.49V software. Number of mice in these experiments are outlined in Table S1. SEM are shown. (C) Immunofluorescence of Rac1–GTP of the pancreata from 2 control, 3 Vav1, 3 K-RasG12D, and 4 K-RasG12D/Vav1 mice, 3.5 mo post-transgene induction was performed. Representative pictures are depicted. Scale bar represents 25 μm. All sections were also stained with anti–Alexa Flour 594 dye for background analysis and found negative.

    Source data are available for this figure.

    Source Data for Figure 6[LSA-2020-00661_SdataF6A_1.pdf][LSA-2020-00661_SdataF6A_2.pdf][LSA-2020-00661_SdataF6A_3.pdf]

  • Fig 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig 7. Treatment of K-RasG12D and K-RasG12D/Vav1 mice with azathioprine.

    At 2 mo after initiation of transgene induction, K-RasG12D and K-RasG12D/Vav1 mice were injected i.p. with azathioprine (Aza; 10 mg/kg), 5 d a week for 1 mo, and euthanized 15 d after the last injection. (A) Representative pictures of hematoxylin and eosin (H&E)–stained sections of pancreata from Aza-untreated (indicated by −) and Aza-treated mice (indicated by +) are shown. Scale bar represents 200 μm. (B) The histogram shows the extent of malignant lesions (APPD%) generated in Aza-treated K-RasG12D and K-RasG12D/Vav1 mice. Numbers of K-RasG12D and K-RasG12D/Vav1 mice used without treatment (−) were n = 8 and n = 12, respectively, and numbers treated with Aza (+) were n = 6 and n = 7, respectively. Significant differences between the two analyzed groups (P < 0.05; t test) are indicated. N.S. refers to statistical nonsignificant differences. SEM are shown. (C) Western blotting using anti–Rac1–GTP Abs, anti-Rac1 and anti-actin were used to evaluate Rac1–GTP levels in protein lysates from pancreatic tissues of Aza-untreated (−) or Aza-treated (+) K-RasG12D and K-RasG12D/Vav1 mice. (D) The relative ratio of Rac1–GTP/Rac1 level was calculated for each group of Aza-untreated (−) or Aza-treated (+) mice. Band intensity of the Western blots was quantified using ImageJ 1.49V software. SEM are shown.

Supplementary Materials

  • Figures
  • Table S1 Number of mice used in various experiments.

  • Table S2 Primers used for transgenic mice genotyping.

  • Table S3 List of antibodies used in this study.

PreviousNext
Back to top
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Synergy: Vav1 and KRasG12D in mouse PDAC
Yaser Salaymeh, Marganit Farago, Shulamit Sebban, Batel Shalom, Eli Pikarsky, Shulamit Katzav
Life Science Alliance Apr 2020, 3 (5) e202000661; DOI: 10.26508/lsa.202000661

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synergy: Vav1 and KRasG12D in mouse PDAC
Yaser Salaymeh, Marganit Farago, Shulamit Sebban, Batel Shalom, Eli Pikarsky, Shulamit Katzav
Life Science Alliance Apr 2020, 3 (5) e202000661; DOI: 10.26508/lsa.202000661
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 3, No. 5
May 2020
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Cancer

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • NLRP3 controls ATM activation
  • RIF1 stabilizes replication domains
  • Chromatin context-dependent interferon response
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2023 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.